Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and best dose of bortezomib when given together
with daunorubicin and cytarabine and to see how well it works in treating older patients with
previously untreated acute myeloid leukemia. Bortezomib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Giving bortezomib together
with combination chemotherapy may kill more cancer cells.